Ifnar2 mutants, their production and use
CA 2470245 C · Owner: Yeda Research And Development Co. Ltd. · Inventors: Schreiber, Gideon
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to mutant polypeptides of the beta chain of the type I IFN receptor (IFNAR2 mutant) with enhanced affinity for interferon-beta as compared to the wild type protein for prolonging the effect of IFN-beta in vivo.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 31, 2002 and granted March 27, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 31, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 31, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.